<DOC>
	<DOCNO>NCT01127659</DOCNO>
	<brief_summary>The purpose study examine effect testosterone deficiency men diabetes obesity . The study also evaluate effect testosterone therapy . This do comparing change several body response indicator follow treatment testosterone diabetic obese-non diabetic men low testosterone level compare diabetic obese-non diabetic men low testosterone treat testosterone .</brief_summary>
	<brief_title>Testosterone Replacement Men With Diabetes Obesity</brief_title>
	<detailed_description>Hypogonadotropic hypogonadism ( HH ) occur approximately one-third obese type 2 diabetic men . Considering 24 million diabetic 100 million obese people , half male , obesity type 2 diabetes potentially constitute major cause hypogonadism population . We hypothesize 1 ) HH obese type 2 diabetic men associate decreased insulin sensitivity , increase fat tissue mass , decrease lean body mass , increase inflammatory oxidative stress , impair sexual function depress mood compare diabetic obese men normal testosterone concentration ; 2 ) testosterone replacement 24 week men HH lead improvement parameter . Our propose study would first prospective , randomize trial comprehensively evaluate effect HH insulin sensitivity , body composition , inflammatory oxidative index obese type 2 diabetic subject effect six month T replacement parameter . The study 2 arm ( obese type 2 diabetic arm ) 120 subject Diabetes arm 80 subject obese arm . Half men arm HH half men normal testosterone concentration ( eugonadal men ) . Insulin sensitivity assess hyperinsulinemic-euglycemic clamp . Subcutaneous fat mass lean body mass measure DEXA intra-abdominal ( visceral ) fat mass MRI . All subject undergo hyperinsulinemic-euglycemic clamp , MRI , DEXA give blood urine sample ( measurement inflammatory oxidative stress ) baseline . Men HH randomize receive testosterone placebo gel total 24 week . These men undergo hyperinsulinemic-euglycemic clamp give blood urine sample inflammation oxidative stress 4 week 24 week . MRI DEXA examination carry 24 week men HH . The primary endpoint study define difference whole body glucose uptake hyperinsulinemic-euglycemic clamp hypogonadal eugonadal diabetes patient baseline increase glucose uptake HH subject treatment testosterone 24 week . 30 subject per group ( testosterone placebo gel ) provide adequate power ( 0.8 ) detect significant difference 10 % whole body glucose uptake . Therefore 60 men HH arm diabetes group . For baseline comparison , 60 men normal testosterone concentration also need arm . We recruit 40 obese patient arm . Thus 120 diabetic men 80 obese men study .</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>T2D arm : Males age 3065 year Obese nondiabetic arm : Obese nondiabetic male age 3065 year 1 ) Coronary event procedure ( myocardial infarction , unstable angina , coronary artery bypass , surgery coronary angioplasty ) previous twelve week ; 2 ) PSA &gt; 4ng/ml ; 3 ) Hemoglobin A1c &gt; 8 % ; 4 ) h/o prostate carcinoma ; 5 ) Hepatic disease ( transaminase &gt; 3 time normal ) cirrhosis ; 6 ) Renal impairment ( define GFR &lt; 30 ) ; 7 ) HIV Hepatitis C positive status ; 9 ) Participation concurrent clinical trial ; 10 ) Any lifethreatening , noncardiac disease ; 11 ) Use counter health supplement contain androgen ; 12 ) Use investigational agent therapeutic regimen within 30 day study ; 13 ) prostate nodule severe enlargement digital rectal examination ; 14 ) Use testosterone currently past 4 month ; 15 ) Hematocrit &gt; 50 % ; 16 ) History untreated severe obstructive sleep apnea ( define apneahypopnea index â‰¥30 ) ; 17 ) symptom suggestive severe BPH ; 18 ) Congestive heart failure , class III IV ; 20 ) Known anemia secondary iron , B12 folic acid deficiency ; 21 ) bone marrow disorder myelodysplasia aplastic anemia ; 22 ) currently suffer symptomatic depression , without treatment ; 23 ) history severe depression past needed hospitalization ; 24 ) currently suffer foot ulcer , significant periodontal disease chronic infectious condition ; 25 ) planning child . 26 ) Subjects testosterone testosterone replacement past 4 month exclude .</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>diabetes</keyword>
	<keyword>hypogonadism</keyword>
	<keyword>obesity</keyword>
	<keyword>testosterone</keyword>
	<keyword>insulin sensitivity</keyword>
	<keyword>inflammation</keyword>
</DOC>